GE HealthCare is collaborating with Danish pharmaceutical giant Novo Nordisk to utilize ultrasounds to combat obesity and treat Type-2 diabetes.
The two companies are working together to further develop peripheral-focused ultrasound, a noninvasive therapy that uses ultrasound waves to stimulate the nervous system and ultimately treat Type-2 diabetes and stimulate weight loss. GE HealthCare said there is early clinical evidence to suggest targeted ultrasound waves may impact glucose metabolism by stimulating nerve pathways.
“In an era where diabetes is increasing around the globe, we are enthusiastic about the potential for ultrasound to help people live healthier lives,” Roland Rott, president and CEO of ultrasound at GE HealthCare, said in a statement. “This collaboration with Novo Nordisk opens a path to evolve ultrasound from a means of screening and diagnosis into therapy, as well. We are eager to validate and further develop this potentially groundbreaking science, as we strive to offer patients alternative treatment options for chronic diseases.”
As part of the collaboration, GE HealthCare and Novo Nordisk will combine their respective expertise in ultrasound medical technology.
GE HealthCare has been making headlines recently for its advances in ultrasound. Just this month, the company announced an AI-guided assistant feature for its systems. It also secured a $44 million federal contact to utilize ultrasounds in a potential disaster scenario.
The specifics of the collaboration were not disclosed.
Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.